Potentiated Hsp104 variants confer a therapeutic gain of function and robustly rescue the toxicity of TDP-43 and FUS (implicated in ALS) as well as α-synuclein (implicated in PD)[17, 29]. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.